Další formáty:
BibTeX
LaTeX
RIS
@proceedings{1564640,
author = {Andrašina, Tomáš and Uher, Michal and Rohan, Tomáš and Matkulčík, Peter and Zavadil, Jan and Čechová, Barbora and Jandurová, Lujza and Válek, Vlastimil},
booktitle = {CIRSE 2019},
doi = {http://dx.doi.org/10.1007/s00270-019-02282-x},
keywords = {hepatocellular carcinoma; transarterial chemoembolisation; survival analysis},
language = {eng},
title = {Chemoembolization for treatment of hepatocellular carcinoma: national registry-based analysis},
url = {https://link.springer.com/content/pdf/10.1007/s00270-019-02282-x.pdf},
year = {2019}
}
TY - CONF
ID - 1564640
AU - Andrašina, Tomáš - Uher, Michal - Rohan, Tomáš - Matkulčík, Peter - Zavadil, Jan - Čechová, Barbora - Jandurová, Lujza - Válek, Vlastimil
PY - 2019
TI - Chemoembolization for treatment of hepatocellular carcinoma: national registry-based analysis
KW - hepatocellular carcinoma
KW - transarterial chemoembolisation
KW - survival analysis
UR - https://link.springer.com/content/pdf/10.1007/s00270-019-02282-x.pdf
L2 - https://link.springer.com/content/pdf/10.1007/s00270-019-02282-x.pdf
N2 - Purpose: To evaluate survival beneft in patient undergoing transarterial chemoembolization for hepatocellular carcinoma by national registry data analysis and comparison of regions with unequal usage of interventional radiology procedures. Material and methods: 4343 patients with primary diagnosis of HCC between 2010-2016 were extracted from the databases of The Czech National Cancer Registry. The analysis was supported by data from the National Registry of Paid Health Services and the Death Records Database. Primary treatment option was categorized as liver resection, ablation, TACE and chemotherapy. The regional data analysis provided information of IR procedures frequency for primary treatment of HCC. The 14 main regions were symmetrically divided to group with welldeveloped IR service and low-developed IR service according to the frequency of stage-adjusted IR procedure usage (<15%,>15%). Kaplan-Meier and Cox regression were used for survival and hazard ratios analyses. Results: Only 1730 patients had assessed any primary treatment option, 16.5% (285) were treated by TACE. Median of survival were signifcantly diferent in regions with well and low developed IR service for whole study population (13.2 months vs 6.5, p< 0.001), patients treated in regions with well developed IR service had lower risk of death during treatment (HR=0.73 (0.66-0.81). The patient treated by TACE had median of survival 15.8 months (13.5-18.1), while the survival was not signifcantly diferent in region groups. Conclusion: The usage of anticancer therapies based on IR procedures is a huge factor infuencing the survival of HCC patient according to population-based data. Studies gathering data from cancer register databases can provide further information on treatment efectiveness.
ER -
ANDRAŠINA, Tomáš, Michal UHER, Tomáš ROHAN, Peter MATKULČÍK, Jan ZAVADIL, Barbora ČECHOVÁ, Lujza JANDUROVÁ a Vlastimil VÁLEK. Chemoembolization for treatment of hepatocellular carcinoma: national registry-based analysis. In \textit{CIRSE 2019}. 2019. ISSN~1432-086X. Dostupné z: https://dx.doi.org/10.1007/s00270-019-02282-x.
|
